- Details
- Description
-
Packaging Size28t/Bottle
-
Strength150mg
-
CompositonAlpelisib
-
TreatmentHR (+) positive, HER2 (-) negative, PIK3CA-mutated, breast cancer
-
FormTablet
-
BrandLuciAlpe
-
Quantity Unit150mg*28t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Alpelisib
Alpelisib is a medication used to treat certain types of breast cancer. It is used together with fulvestrant. It is an alpha-specific PI3K inhibitor.
Breast Cancer
Kinase inhibitor indicated in combination with fulvestrant for treatment of men and pre-, peri-, or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen
Alpelisib 300 mg PO qDay AND
Fulvestrant 500 mg IM on Days 1, 15, and 29, and once monthly thereafter
Continue treatment until disease progression or unacceptable toxicity occurs
Refer to the full prescribing information for fulvestrant
PIK3CA-Related Overgrowth Spectrum
Vijoice onlyIndicated for severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in patients who require systemic therapy
250 mg PO qDay
Continue until disease progression or unacceptable toxicity
